T1	Participants 105 144	chemotherapy for advanced solid tumors:
T2	Participants 331 406	227 patients with breast, colorectal, lung and other solid forms of cancer.
T3	Participants 518 536	MPA (117 patients)
T4	Participants 540 563	placebo (110 patients).
